Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | NPC1 | O15118 | 4/20 | 0.63 |
| ▸ | RAB9A | P51151 | 4/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1420033 | 0.82 | TP53 (0.81) | MAPTNPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL18901151 | 0.81 | NPC1 (0.63) | MAPTNPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL6902568 | 0.81 | NPC1 (0.63) | MAPTNPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL2434743 | 0.81 | RAB9A (0.58) | MAPTNPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL2432870 | 0.80 | RAB9A (0.56) | MAPTNPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL2621291 | 0.79 | MAPT (0.70) | MAPTNPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL31276462 | 0.79 | MAPT (0.70) | MAPTNPC1RAB9ASMN1; SMN2TP53 | |
| Fluoride SCHEMBL7598310 | 0.79 | TP53 (0.75) | MAPTNPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL20353955 | 0.78 | ELANE (0.68) | MAPTNPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL155002 | 0.78 | MAPT (1.00) | MAPTNPC1RAB9ASMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250043353-A1 | BIOMARKERS OF RESPONSE TO SELECTIVE INHIBITORS OF AURORA A KINASE | MILLENNIUM PHARM INC (US) | 2025-02-06 | — | — | US | disclosed |
| EP-3016951-B1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-05-31 | — | — | EP | disclosed |
| US-20160152628-A1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-06-02 | — | — | US | disclosed |
| US-20130310373-A1 | PYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-11-21 | — | — | US | disclosed |
| US-8524727-B2 | Pyrimidine compound | ASTELLAS PHARMA INC. (JP) | 2013-09-03 | — | — | US | disclosed |
| US-8524727-B2 | Pyrimidine compound | ASTELLAS PHARMA INC. (JP) | 2013-09-03 | — | — | US | disclosed |
| EP-2415765-A1 | PYRIMIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20110053912-A1 | PYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-03-03 | — | — | US | disclosed |
| US-20110053912-A1 | PYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-03-03 | — | — | US | disclosed |
| WO-2010113834-A1 | PYRIMIDINE COMPOUND | アステラス製薬株式会社 (JP) | 2010-10-07 | — | — | WO | disclosed |
| EP-0767792-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2002-11-20 | — | — | EP | disclosed |
| US-5977101-A | Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity | SMITHKLINE BEECHAM CORPORATION (US) | 1999-11-02 | — | — | US | disclosed |
| CN-1156995-A | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 1997-08-13 | — | — | CN | disclosed |
| EP-0767792-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-04-16 | — | — | EP | disclosed |
| WO-1996000730-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-01-11 | — | — | WO | disclosed |
| US-5104892-A | N-heteroalkyl substitutes 1-aryloxy-2-propanolamine | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-04-14 | — | — | US | disclosed |
| US-5084463-A | Cardiovascular disorders | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-01-28 | — | — | US | disclosed |
| WO-1991009023-A1 | N-HETEROARALKYL-SUBSTITUTED 1-ARYLOXY-2-PROPANOLAMINE AND PROPYLAMINE DERIVATIVES POSSESSING CLASS III ANTIARRHYTHMIC ACTIVITY | AMERICAN HOME PRODUCTS CORPORATION (US) | 1991-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152628-A1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | MYLK, MYLK2, ROCK1 | MAPT 184/4885NPC1 4667/4885RAB9A 1385/4885 |
| US-20250043353-A1 | BIOMARKERS OF RESPONSE TO SELECTIVE INHIBITORS OF AURORA A KINASE | WNT1, XPOT, CTNNBL1 | MAPT 458/4885NPC1 2556/4885RAB9A 3071/4885 |
| US-20110053912-A1 | PYRIMIDINE COMPOUND | CNR2, CNR1, P2RY2 | MAPT 2938/4885NPC1 2248/4885RAB9A 2804/4885 |
| US-20130310373-A1 | PYRIMIDINE COMPOUND | CNR2, CNR1, P2RY2 | MAPT 3111/4885NPC1 2300/4885RAB9A 2695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.